Intra-Cellular Therapies ...

NASDAQ: ITCI · Real-Time Price · USD
131.87
0.00 (0.00%)
At close: Apr 01, 2025, 3:59 PM

Intra-Cellular Therapies Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net Income
-74.68M -139.67M -256.26M -284.13M
Depreciation & Amortization
-8.52M 528K 656K 533.36K
Stock-Based Compensation
64.03M 52.83M 43.01M 34.3M
Other Working Capital
-1.33M 34.54M 11.16M 740.84K
Other Non-Cash Items
82K -8.31M 537K 178.53K
Deferred Income Tax
n/a n/a n/a -4.08M
Change in Working Capital
-54.1M -29.58M -58.14M -6.35M
Operating Cash Flow
-73.18M -124.2M -270.19M -259.54M
Capital Expenditures
-322K -269K -778K -325.74K
Cash Acquisitions
n/a n/a 127.59M -280.67M
Purchase of Investments
-739.68M -415.27M -759.21M -224.57M
Sales Maturities Of Investments
404.85M 521.08M 631.61M 505.24M
Other Investing Acitivies
n/a n/a -127.59M 280.67M
Investing Cash Flow
-335.15M 105.54M -128.37M 280.34M
Debt Repayment
n/a n/a n/a n/a
Common Stock Repurchased
n/a n/a n/a n/a
Dividend Paid
n/a n/a n/a n/a
Other Financial Acitivies
24.42M 17.81M 21.44M 11.52M
Financial Cash Flow
567.51M 17.81M 455.16M 11.52M
Net Cash Flow
159.18M -848K 56.6M 32.32M
Free Cash Flow
-73.5M -124.47M -270.96M -259.87M